A carregar...

Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma

Denileukin diftitox (Ontak(®)) is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare lymphoproliferative disorder of the skin. Denileukin diftitox was the first fusion protein toxin approved for the treatment of a human disease. This fusion...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lansigan, Frederick, Stearns, Diane M, Foss, Francine
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3004568/
https://ncbi.nlm.nih.gov/pubmed/21188096
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!